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Abstract
Artemisinin resistance is a major threat to malaria control efforts. Resistance is character-
ized by an increase in the Plasmodium falciparum parasite clearance half-life following
treatment with artemisinin-based combination therapies (ACTs) and an increase in the per-
centage of surviving parasites. The remarkably short blood half-life of artemisinin derivatives
may contribute to drug-resistance, possibly through factors including sub-lethal plasma con-
centrations and inadequate exposure. Here we selected for a new strain of artemisinin resis-
tant parasites, termed the artemisinin resistant strain 1 (ARS1), by treating P. falciparum
Palo Alto (PA) cultures with sub-lethal concentrations of dihydroartemisinin (DHA). The
resistance phenotype was maintained for over 1 year through monthly maintenance treat-
ments with low doses of 2.5 nM DHA. There was a moderate increase in the DHA IC50 in
ARS1 when compared with parental strain PA after 72 h of drug exposure (from 0.68 nM to
2 nM DHA). In addition, ARS1 survived treatment physiologically relevant DHA concentra-
tions (700 nM) observed in patients. Furthermore, we confirmed a lack of cross-resistance
against a panel of antimalarials commonly used as partner drugs in ACTs. Finally, ARS1 did
not contain Pfk13 propeller domain mutations associated with ART resistance in the Greater
Mekong Region. With a stable growth rate, ARS1 represents a valuable tool for the develop-
ment of new antimalarial compounds and studies to further elucidate the mechanisms of
ART resistance.
Introduction
Plasmodium falciparum is the most lethal of the malaria known to infect humans [1], and
was responsible for nearly 212 million new cases and 429.000 deaths in 2016 [2]. Artemisinin
derivatives (ART) represent the most widely used anti-malarial drugs. Derived from the plant
Artemisia annua, ART contain an endoperoxide ring essential for its potent and rapid antima-
larial activity [3, 4]. Although ring-stage parasites are most sensitive to drug treatment, ART
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are active against all asexual stages of parasite development [5]. Unfortunately, the use of ART
as mono-therapies has contributed to the increase and spread of artemisinin resistant para-
sites, and remains a major threat for malaria control efforts in South East Asia [6]. Although
artemisinin derivatives are now only used in combination with slow-acting partner drugs as
ACTs to deter drug—resistance, however, resistance to partner drugs has been detected [7, 8],
further necessitating the development of new and effective antimalarials [9, 10].
Artemisinin resistance is defined by a delay in parasite clearance following 3 days (DPC3)
of treatment with ACTs, but, many times, parasites become resistant to the partner drug in
addition to ART [11]. Partner drug resistance is characterized by recrudescence of the infec-
tion after 28 or even 42 days following ACT treatment [12]. For this reason, malaria parasite
are evaluated 3 days and 28 days following treatment for a lack of adequate clinical and parasi-
tological response at day 28 (ACPR28) [13, 14, 15, 16]. ART rely on their rapid conversion to
reactive free radicals for potent antimalarial activity. However, their very short clearance half-
life (~1h) combined with under dosage of infected patients and incomplete drug treatment
may contribute to the occurrence and spread of ART resistance [17, 18, 19]. Exacerbating the
situation, patients frequently undergo incomplete treatment [20, 21]. ART resistant parasites
may have acquired the ability to survive under the sub-lethal drug concentrations or insuffi-
cient exposure to artemisinin, similar to that seen in bacterial resistance to antimicrobial
agents [22, 23, 24].
Stable ART resistant strains of P. falciparum, have been obtained from infected patients
while others have been manipulated to induce artemisinin resistance by subjecting parasites to
increasing concentrations of DHA in vitro [22, 25, 26, 27].
The heterogeneity and number of factors that can contribute to ART resistance have been
evidenced by the amount of studies performed in a similar manner in vitro [28, 29]. Interest-
ingly, the over-expression of P. falciparum malaria genes related to cell repair mechanisms
have been identified and not only support research demonstrating ART generate free radicals
for antimalarial activity, but also the rapid response of parasites to increasing drug pressure by
inducing a series of protective and repair mechanisms [30, 31].
Laboratory-adapted strains of P. falciparum contain phenotypes uncharacteristic to those
found in clinical isolates, or parasite resistance found in patients [32]. While all these strains
may be ART resistant, not all artemisinin resistance phenotypes are the same. In addition, the
type manipulation used to induce artemisinin resistance in vitro can induce a similar unchar-
acteristic phenotype. For example, a large number of dormant parasites are induced by short
treatments with high DHA concentrations, but evidence of similarly dormant parasites during
infection is lacking [33].
Finally, it has been reported that mutations in the P. falciparum kelch-13 propeller (Pfk13)
gene are associated with ART resistant malaria in the Greater Mekong Sub-region and in
China-Myanmar [34, 35, 36]. It has been suggested this resistance is due to the dysregulation
of Phosphatidylinositol 3-phospate metabolism, which is critical for parasite survival [37, 38,
39]. Although ACTs have been widely used for over a decade, no Pfk13 propeller mutations
associated with ART resistance have been reported for in African P. falciparum populations
[40, 41]. These results strongly support the involvement of multiple factors with delayed para-
site clearance after ACT treatment and the importance of preventing parasite tolerance to the
partner drug.
With these findings in mind, we set out to select an artemisinin resistant strain by exposing
parasites to sub-lethal DHA concentrations and then progressively shortening the time inter-
vals between drug treatments. Cultures were monitored, taking great care to prevent the accu-
mulation of dormant parasites. We now present a novel P. falciparum artemisinin resistant
strain (ARS1) that possess a high tolerance against sub-lethal DHA concentrations and this
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stable strain will help elucidate ART resistance mechanisms and direct efforts to test new anti-
malarial compounds.
Materials and methods
Plasmodium falciparum cultures
Three P. falciparum parasites strains were used in this study and obtained from field isolate.
The Palo Alto (PA) strain was isolated from a Ugandan patient and is considered as a reference
strain due to its high genetic stability. PA has historically been used as a strain to study drug
susceptibility in P. falciparum in vitro [42]. The FCR3 strain derived from Gambian parasites
and is genetically related with PA and it has been used to generate a chloroquine (CQ) and
pyrimethamine (PM) resistant strain [22, 42]. The HB3A parasites strain derived from Hondu-
ras and has been used to induce chloroquine resistance [43, 22].
Plasmodium falciparum-infected red blood cell (I-RBC) culture
maintenance
P. falciparum strains PA, FCR3, HB3A and the ARS1 strain, selected in this study (mycoplasma
free), were maintained in culture with fresh red blood cells RBCs (Rh+) from healthy volun-
teers of both sexes. Human blood samples were used only to sustain the parasites in vitro cul-
tures. Blood samples used to perform the present study were obtained from Banca del sangue
C/O Ospedale Molinette, Torino with written informed consent. This study was conducted
in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. No ethi-
cal approval has been requested. RBCs were separated from plasma and leukocytes by three
washes in RPMI 1640 medium containing 25 mM HEPES (R5886 Sigma Aldrich), and then
resuspended in RPMI 1640 + HEPES medium supplemented with 200 mM L-glutamine
(59202C Sigma Aldrich), 2 mM glucose and gentamicin (80 mg/mL). For complete growth
medium, this was further supplemented with 1% SAG-M solution, (150 mM NaCl, 1.25 mM
adenine, 30 mM glucose, 145 mM mannitol) and heat-inactivated human serum. I-RBC cul-
tures were maintained at 2–5% parasitemia (1% haematocrit) at 37˚C in an air/CO2-athmo-
sphere of 95/5% (vol/vol). All assays were performed at this parasitemia and hematocrit unless
otherwise described.
Cultures were synchronized weekly by Percoll separation [44] or 5% sorbitol solution treat-
ment [45]. The synchronization process did not influence the generation or phenotype of the
artemisinin resistant strain. Parasite viability and parasitemia were monitored by Diff-Quick
stained thin blood smears and light microscopy (Carl Zeiss Standard Microscope Lamphouse
467230). Parasitemia was defined as the number of parasites/number of RBCs counted, for a
total of 5000 RBCs. Two thin smears per condition were counted 3 separate times by each of
three operators.
Selection of artemisinin resistant strain 1 (ARS1) following DHA
treatment
DHA (D7439 Sigma-Aldrich) was suspended in sterile dimethyl sulfoxide (DMSO) and subse-
quently diluted in RPMI 1640 + HEPES prior to I-RBC treatment.
For the first week (D1 –D7): i) synchronous cultures of PA, FCR3 and HB3A were supple-
mented daily with three concentrations of DHA (1.25, 2.5 and 5 nM) along with an untreated
control. For cultures with a percentage of viable parasites lower than 1%, the daily treatments
were stopped and only re-applied with a parasitemia of greater than 2.5%. ii) Before every new
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treatment, I-RBC cultures were washed once in RPMI 1640 + HEPES and resuspended in
fresh growth medium containing the same concentration of DHA.
For the next 7 weeks (D8 –D54): i) PA, FCR3 and HB3A were synchronized with 80% Per-
coll every 7–8 days, ii) treated with their respective concentration of DHA once a week (the
day following Percoll synchronization), iii) the growth medium was changed every 24 h. Para-
sitemia was determined every day from the start of the study. When cultures were completely
devoid of viable parasites for at least 7 days (analysing two thin smears every day), the cultures
were considered parasite free. Fig 1 demonstrates parasite morphology from D0 to D54 of the
parental PA strain and the surviving ARS1 strain with the average parasitemia reported as pre-
viously described with two operators and as a percent of the untreated control. To maintain
the ARS1 strain selected from PA: i) ARS1 cultures were synchronized every 7 days with 80%
Percoll to isolate trophozoite stage parasites and treated with Sorbitol 5% 24 h later to isolate
ring stage parasites; ii) cultures were treated with 2.5 nM of DHA monthly at ring stage 24 h
following sorbitol synchronization; iii) parasite cultures were incubated with DHA for 48 h
and then replaced with fresh growth medium which was changed every 48 h; iv) this monthly
DHA treatment was continued for over 1-year period.
Analysis of long-term treatment of strains PA and ARS1 with repeated
DHA treatments
PA and ARS1 were treated with 1.25 and 2.5 nM DHA, respectively every 48 h for a total of
144 h in order to evaluate the PA and ARS1 behaviour assessed with different frequency DHA
pressure (Fig 2) or with 2 nM DHA every 12 or 24 h for a 72 h. Parasitemia was determined as
previously described.
Analysis of DHA’s effect on parasite maturation and death
PA and ARS1 ring stage cultures were treated with 0.6, 1.25, 2.5, 5 and 10 nM of DHA and
evaluated at 24 and 48 h following drug addition. The effect of DHA treatment on P. falcipa-
rum maturation and death was evaluated by determining the parasitemia of each maturation
stages: ring, trophozoite and schizont, and for intracellular dead parasites (pyknotic) in both
DHA-treated and untreated control cultures. The percentage of each stage of live parasite and
the number of dead parasites present in DHA treated cultures were expressed as the % parasi-
temia relative to the untreated cultures.
Rings-stage Survival Assay (RSA0-3h)
The in vitro RSA0-3h assay was performed using the method described by Worldwide Antima-
larial Resistance Network (WWARN) (2013) and by Witkowski et al. to demonstrate the pres-
ence of reduced sensitivity to DHA in the newly selected ARS1 strain [46, 47, 48].
Briefly, the 0–3 h post invasion, ring stage parasites were exposed to 700 nM DHA for 6 h.
The cultures were washed to remove the drug and then cultured with the complete medium
for additional 66 h. The proportion of viable parasites was counted in the second generation
parasites with normal morphology.
As described by the WHO guidelines, we calculated the survival rate (%) and the growth
rate: i) the percentage of survival rate was defined as the DHA-exposed parasitemia at 72 h/
non-exposed parasitemia at 72 h x 100; ii) the growth rate was defined as the non-exposed
parasitemia at 72 h/the initial parasitemia at 0 h. Every thin smear were counted by microscopy
via Giemsa stained evaluating a total of 10000 RBCs. Two thin smears per condition were
counted 3 separate times by each of three operators. Values obtained for % of survival rate of
DHA-treated are interpretable if they correspond to a growth rate 1.5%.
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IC50 of P. falciparum strains treated with antimalarial drugs
Synchronous ring stage cultures of strains PA, ARS1, FCR3 and HB3A were treated with
DHA, mefloquine (MQ), piperaquine (PPQ), amodiaquine (AQ) and lumefantrine (LMF) and
parasitemia checked every 24 h following drug treatment. The scalar concentrations of each
drug included 0.6, 1.25, 2.5, 5,10, 20 and 40 nM for DHA and 5, 10, 25, 50, 75, 100 and 200 nM
for AQ, MQ, PPQ and LMF. To determine the IC50 of each drug, cultures were treated with a
Fig 1. Response of P. falciparum cultures PA, FCR3, HB3A and ARS1 to DHA. PA (A), FCR3 (B), HB3A (C) and ARS1 (D) cultures were first treated daily with
1.25, 2.5 and 5 nM for 1 week and then treated weekly for 7 weeks, for a total of 54 days. Mature and immature parasites were counted. Data were normalized the
parasitemia of untreated cultures determined by light microscopy of Giemsa-stained smears. Mean +/- SD of 5 independent experiments is shown.
https://doi.org/10.1371/journal.pone.0191084.g001
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Fig 2. Survival of ARS1 to increased frequency of DHA treatments every 48 h. PA and ARS1 were analysed without
treatment (A) and after repeated treatments every 48 h with 1.25 nM (B) or 2.5 nM (C) DHA, by counting mature and
immature parasites. Data were normalized to the control parasitemia and analysed by light microscopy of Giemsa-
stained thin smears. The medium was changed every 48 h. Mean +/- SD of 5 independent experiments is shown.
Significant differences between strains are indicated by () at p< 0,05 and () at p< 0,01.
https://doi.org/10.1371/journal.pone.0191084.g002
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single-pulse of drug and incubated for 48 h [49, 28, 50]. IC50 values were determined using
ICestimator software by schizont counting (http://www.antimalarial-icestimator.net/
runregression1.2.htm) [51]. The half-life was considered relevant when the R2 value of the
slope regression line was higher than 0.8.
Treatments with DHA and MQ combined
PA and ARS1 cultures were treated with DHA alone or in combination with MQ to determine
if there is synergism between the two drugs and whether ARS1 is sensitive to this type of ACT.
Cultures were synchronized using Percoll/5% sorbitol treatment and assay initiated at a 5%
parasitemia and 1% haematocrit. IC50 values determined at 24, 48 and 72 h following drug
treatment: DHA (0.6, 1.25, 2.5, 5, 10, 20 and 40 nM) +/- supplemented with 5 or 10 nM MQ
where described.
P. falciparum DNA extraction
A salting out method was used to extract parasite DNA from 100μL of I-RBCs according to
standard procedures by Miller et al. [52]. Briefly, RBCs were lysed with Red Cells Lysis Buffer
(RCLB) solution (Tris-HCl 10 mM, MgCl2 5 mM and NaCl 10 mM, pH 7.6) and the cell pellet
isolated and incubated at 55˚C for 20’with White Cells Lysis Buffer (WCLB) solution (Tris-
HCl 10 mM, EDTA 10 mM and NaCl 50 mM, pH 7.6) in the presence of SDS (10%) and pro-
teinase K (20 mg/ml). The addition of a saturated salt solution (NaCl 6M) purified the DNA,
which was then precipitated following the addition of isopropanol. After a 70% ethanol wash,
the final DNA pellet was re-suspended in sterile H2O and analyzed for purity by determining
the ratio of absorbance at 260 and 280 nm.
Nested-PCR analysis of strains PA and ARS1 cultures
Sequencing the Pfk13propeller domain. The P. falciparum k13 propeller domain gene
was evaluated for any mutations by using nested PCR to amplify the gene previously described
by Ariey et al. [32]. Amplified PCR products were purified using Exo I & Fact AP (Carlo Erba)
and sequenced by Macrogen, Inc. (Netherlands). Electroferograms were visualized and ana-
lyzed with ApoE software, and alignments were performed with Muscle 3.8 software using the
k13 sequence of the 3D7 clone (PF3D7_1343700) as the reference standard.
Genotyping of msp1, msp2 and glurp with nested-PCR in PA and ARS1 strain. The
genetic characteristics of P. falciparum polymorphic genes, such as the Merozoite Surface pro-
teins 1 and 2 (msp1 and msp2) and the Glutamate-rich protein (glurp) are commonly assessed
in malaria endemic areas to discriminate recrudescence from re-infecting parasites alleles.
Nested PCR was used to amplify the polymorphic regions of msp1, msp2 and glurp using fam-
ily-specific primers, previously described by Snounou [53].
Briefly, in the primary reaction, oligonucleotide primers corresponded to conserved
sequences within msp1 (block 2), msp2 (block 3) and glurp in the primary reaction. In the
nested reaction, separate primer pairs were used that targeted the respective allelic types of
msp1 (K1, MAD20, and RO33) msp2 (FC27 and IC3D7) and glurp were used [54]. The PCR
products were separated on 1.5% agarose and visualized under UV illumination.
Statistical analysis
Error bars indicate the average ± SD. The statistical significance is estimated with two-tailed
Student’s t-test performed with Microsoft Excel software.
A new in vitro model of P. falciparum
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Results
Selection for a new artemisinin resistant strain
We first performed experiments to select for artemisinin resistant parasites by experimentally
determining the lowest concentration of DHA that would enable continuous culture of P. fal-
ciparum strains PA, FCR3 and H3BA when subjected to intermittent sub-lethal drug exposure.
The IC50 values (Table 1) among the three strains revealed slight variations in sensitivity to
DHA treatment. The IC50 values of DHA in HB3A after 24 and 48 h, 2.14 and 2.27 nM, respec-
tively, were higher than PA and FCR3 and supported by Ding et al. and Cui et al. [28, 29]. Var-
iations in DHA sensitivity among the malaria strains can be attributed to the nature of each
individual strain such as their origin, laboratory adaptation, and length of propagation [22]. In
addition we obtained IC50 values at 24 h in addition to the 48 h and 72 h due to the characteris-
tic short half-life of DHA in patients and in cultures and to evaluate its final antimalarial effi-
cacy [55]. These IC50 values provided a baseline that was used to evaluate parasite sensitivity to
DHA during the selection process.
For the selection process, parasite cultures were exposed to 1.25, 2.5 and 5 nM DHA every
24 h for 1 week, then washed and resuspended in drugless medium for at most 7 weeks, which
included a single exposure for 24 h every week (see Materials and methods). Over time, PA
cultures gained the ability to grow at a consistent rate during the weekly treatments with 1.25
nM DHA (Fig 1A). We never observed the same drug-adaptation with FCR3 or HB3A (Fig 1B
and 1C). A slight growth recovery was observed during week 2 in HB3A but parasitemia
declined sharply and flat lined by day 12 (Fig 1C). The higher DHA concentrations (2.5 and 5
nM) were toxic to the parasites and failed to select for any drug resistant parasites. We moni-
tored the parasitemia of PA, FCR3, and HB3A so long as: i) there were viable parasites growing
in culture and ii) the growth rate was consistent or increased over a period time. The evalua-
tion of FCR3 and HB3A were terminated prematurely due to the complete lack of viable
parasites 22 and 38 days following DHA treatment, respectively. PA was monitored for the
duration of the 8-week study. After daily application of DHA during the first week, PA cultures
alone contained viable parasites and the cultures appeared to be desensitized to DHA and,
thus, were renamed to artemisinin resistant strain 1 (ARS1). ARS1 was evaluated for a total of
54 days after which the growth rate stabilized (the stabilization of the culture started on 32nd
Table 1. IC50 values of DHA, MQ, PPQ, AQ, LMF treated cultures of P. falciparum strains PA, ARS1, FCR3 and HB3A.
Strain of P. falciparum Drug in vitro tested IC50 ± SD (24 h) IC50 ± SD (48 h) IC50 ± SD (72 h)
PA DHA 2.21 ± 0.4 nM 0.94 ± 0.1 nM 0.68 ± 0.2 nM
MQ 19.75 ± 0.3 nM 6.30 ± 0.1 nM 5.49 ± 0.92 nM
PPQ 20.93 ± 1.4 nM 19.19 ± 1.9 nM 16.20 ± 1.1 nM
AQ 21.03 ± 1.4 nM 15.80 ± 1.8 nM 14.05 ± 2.1 nM
LMF 22.64 ± 0.2 nM 18.50 ± 2.4 nM 17.12 ± 0.8 nM
ARS1 DHA 3.17 ± 0.5 nM 2.5 ± 0.2 nM 2.0 ± 0.3 nM
MQ 18.66 ± 1.8 nM 5.54 ± 0.7 nM 4.78 ± 0.6 nM
PPQ 19.90 ± 1.7 nM 11.66 ± 0.8 nM 8.65 ± 0.3 nM
AQ 19.46 ± 0.6 nM 14.45 ± 1.4 nM 14.2 ± 0.8 nM
LMF 21.29 ± 1.3 nM 17.55 ± 2.4 nM 16.99 ± 1.52 nM
FCR3 DHA 1.73 ± 0.6 nM 1.60 ± 0.3 nM N/D
HB3A DHA 2.14 ± 0.3 nM 2.27 ± 0.05 nM N/D
DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; AQ, amodiaquine; LMF, lumefantrine.
All experiments were performed at least five times independently. Values are expressed in percentage of viable parasites ± SD.
https://doi.org/10.1371/journal.pone.0191084.t001
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day) and parasites consistently displayed low susceptibility to the same DHA concentration
used during the selection period. At 5 nM, ARS1 was still capable of maintaining a survival
rate of 20%, corroborating our initial findings. It appeared that the actual selection for ARS1
was made after the first week of daily DHA treatments and the following 7 weeks of weekly
1.25 and 2.5 nM DHA treatments served to maintain this new strain with decreased sensitivity
to DHA (Fig 1D). Similarly, a 40% increase in IC50 was observed in ARS1 when compared
with values from parental strain PA, 48 h following exposure to DHA (Table 1).
A key response of resistant parasite populations to sub-lethal drug concentrations was to
recover following treatment, evidenced by an increase in parasitemia. Recovery times are spe-
cific to each strain used to the antimalarial mechanism, and so, we reduced the time interval
between DHA treatments from weekly to every 48 h (Fig 2). Growth curves of ARS1 and PA
are comparable in the absence of DHA (Fig 2A). Following the addition of 1.25 nM (Fig 2B)
and 2.5 nM (Fig 2C) DHA treated every 48 h, only ARS1 parasitemia remained increased by
400% and 80%, respectively, from the initial value. On the other hand, PA cultures did not sur-
vive similar DHA treatments and parasitemia progressively decreased. These findings suggest
that damage inflicted on ARS1 is reversible since the parasites were able to proliferate under
these DHA concentrations.
While monitoring parasite recovery during the previous DHA treatments, the stage syn-
chronicity of ARS1 decreased compared to PA. To better understand the effect of DHA on
parasite maturation and death, ring-stage cultures were exposed to increasing concentrations
for 48 h (Fig 3). As indicated by the relative percentage of rings, trophozoites, schizonts and
dead parasites, a high number of parasites survived in ARS1 at concentrations up to 10 nM by
24 h, but decreased to levels observed in PA by 48 h. A significant amount of ARS1 parasites
survived at lower DHA concentrations compared with PA. Untreated cultures were at the
expected ring stage. The presence of trophozoites and schizonts in ARS1 signified parasite
maturation was negatively affected and slower than untreated cultures. Overall, the percentage
of immature parasites was higher in ARS1 than in PA at both 24 h (Fig 3A and 3B) and 48 h
(Fig 3C and 3D). It’s possible that the DHA treated ARS1 parasites entered a state of quies-
cence at the ring stage or their development is delayed after 24 h which could confer the arte-
misinin tolerance.
This set of experiments demonstrates the ability to select for an artemisinin resistant strain
from an initially sensitive to DHA by using sub-lethal concentrations. The results suggest that
resistant parasites may be selected for during the first division cycles that follow sub-lethal
damage exerted by DHA.
Characterization of the newly generated ARS1 strain
We next sought to evaluate ARS1 resilience to continuous drug pressure, so we replenished
cultures with 2 nM DHA every 12 or 24 h. Replacement every 12 h was nearly lethal to ARS1,
which appeared to require a longer period of time for parasite recovery between drug treat-
ments. The decrease in parasitemia of ARS1 paralleled that of PA (Fig 4A). Replacement of
DHA every 24 h reflects drug treatment schedule in patients. ARS1 survived this type of treat-
ment, while it was lethal to PA, killing nearly 100% of parasites after 3 days of treatment (Fig
4B). On the contrary, ARS1 had a growth rate similar to that of untreated ARS1 cultures.
To maintain a drug resistance phenotype in vitro, it is critical to know the maximum time
interval that can be allowed between drug treatments. This helps to evaluate a strain’s stability
of drug resistance. Over 1-year period, we treated ARS1 with DHA concentrations up to 20
nM to determine the minimum concentration and maximum period of time ARS1 parasites
maintain the artemisinin resistant phenotype.
A new in vitro model of P. falciparum
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After 2–3 months without DHA pressure, ARS1 lost its resistant phenotype. Parasites con-
tinue to carry the previously characterized phenotype with at least 1.25 nM DHA administered
monthly. It was under monthly treatments with 2.5 nM DHA that the resistance phenotype
was conserved for over 1 year. Repeated freezing and thawing of cultures using the standard
protocols that employ high concentrations of glycerol did not affect this resistance either.
The Rings-stage Survival Assay (RSA0-3h) is a common assay to assess a parasite tolerance
to DHA or other antimalarial drug. Briefly, parasite cultures were exposed to a single pulse
of 700 nM DHA for 6 h using young ring-stage parasites 0-3h post-invasion after culture
Fig 3. Effect of PA and ARS1 on parasite maturation following DHA treatment. The percentages of rings, trophozoites, schizonts and dead parasites were
determined after treatment of ring stage parasitized cultures of the PA (A, C) and ARS1 (B, D) strains exposed to 0.6, 1.25, 2.5, 5 and 10 nM of DHA for 48 h.
Parasitemia was measured at both 24 h (A) (B) and 48 h (C) (D) after treatment via light microscopy of Giemsa-stained thin smears. Data were normalized to the
untreated control parasitemia. The differences of immature parasites stage of ARS1 compared to PA are indicated by: (a) p< 0.05 at 24 h, (b) p< 0.05 at 48 h.
https://doi.org/10.1371/journal.pone.0191084.g003
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adaptation. This type of treatment exemplifies DHA’s short half-life in patients in addition to
assessing parasite tolerance to a physiologically relevant dose of DHA. Supporting previous
results, ARS1 possessed a higher tolerance to 700 nM DHA than PA, where a remarkable drop
in parasitemia was observed. Results of this assay are represented by the survival rate (%) of
Fig 4. Effect of constant DHA pressure on PA and ARS1 cultures. PA and ARS1 were treated every 12 h (A) and 24
h (B) for up to 72 h, with 2 nM of DHA. Parasitemia was determined by microscopy of Giemsa-stained thin smears
and normalized on the control parasitemia. Control parasitemia was determined from untreated PA and ARS1 strains
maintained under the same conditions as the DHA treated. Means +/- SD of 3 independent experiments is shown.
Significant differences of parasitemia between strains are indicated by () at p< 0.05, () at p< 0.01 and () at
p< 0.001.
https://doi.org/10.1371/journal.pone.0191084.g004
A new in vitro model of P. falciparum
PLOS ONE | https://doi.org/10.1371/journal.pone.0191084 January 17, 2018 11 / 18
PA and ARS1 that correspond to 0.51% and 6.8%, respectively. The percent survival rate is
interpretable if the growth rate is 1.5 (see Materials and methods). In fact, the growth rate of
PA and ARS1 was 8.2 ± 4.1 and 4.7 ± 0.8, respectively (Table 2).
In this assay, the resistance to treatment appears not due to its ability to enter a dormant or
quiescent state but to the ability of ARS1 to recover and overcome the effects of DHA treat-
ment (S1 Fig).
This set of experiments show that ARS1 not only possesses quite stable characteristics in
terms of IC50, but, even more important, the marked capability of ARS1 strain survival at a
constant rate with DHA concentrations that kill 100% of parental PA strain parasites following
3 days of treatment. In addition, ARS1 survived under the RSA0-3h conditions mimicking
those present in plasma of drug-treated patients.
Sensitivity of ARS1 to treatment with other antimalarials
ART are no longer used as mono-therapies to treat malaria infections and are now only pre-
scribed in combination with a partner drugs as ACTs. Partner antimalarials are complimen-
tary to ART and serve to compensate for the short half-lives of ARTs and improve parasite
clearance by counteracting the selection of resistant parasites.
Unfortunately, artemisinin resistance has been observed in patients treated with ACTs and
for this reason, it was necessary to assess ARS1 for multidrug resistance to commonly used
anti-malarial drugs with longer half-lives. IC50 values were determined at 24, 48 and 72 h fol-
lowing treatment to evaluate parasite response MQ, AMQ, LMF and PPQ (Table 1). The IC50
concentrations of these four drugs were similar in both ARS1 and PA and parasites susceptible
to each antimalarial.
Cultures were then treated with DHA and MQ, a combination commonly used in ACTs
where the long half-life of MQ compensates for the fast acting but short lived DHA.
The addition of MQ greatly decreased the IC50 against PA, signifying an increase in sensi-
tivity to DHA while ARS1 sensitivity remained relative stable (Fig 5). The parasitemia was
assessed and multiple time points to evaluate the antimalarial effect of DHA on the cultures
and the response to long-acting MQ. ARS1 resistance appeared to be selective for a DHA. The
DHA IC50 after 72 h correspond to 0.68 ± 0.2 nM and to 2 ± 0.1 nM for ARS1 while the IC50 of
MQ alone after 72 h correspond to 5.49 ± 0.92 nM for PA and 4.78 ± 0.6 nM for ARS1.
Finally, mutations in the Pfk13 gene have been associated with ART resistance in ex vivo
assays with P. falciparum strains obtained from the eastern Greater Mekong sub-region (Cam-
bodia, Laos and Vietnam). The most common polymorphisms include C580Y, R539T, I543T
and Y493H, so we sequenced the same regions in ARS1 and PA strains to help elucidate the
underlying cause of this artemisinin phenotype. These regions were found to be identical in
the two strains, eliminating this as possible causes of artemisinin resistance. Moreover, geno-
typing the msp1, msp2 and glurp genes, commonly used to differentiate reinfection from recru-
descence in patients infected with malaria. This supports our findings that revealed no genetic
Table 2. Growth rate and survival rate (%) in in vitro RSA0-3h with 700 nM DHA at 72 h after ARS1 selection.
Strain of P. falciparum Growth rate Survival rate (%) p-value vs PA
PA 8.2 ± 4.1 0.51 ± 0.46 /
ARS1 4.7 ± 0.8 6.8 ± 0.58 0.011
Values of growth rates are expressed as non-exposed parasitemia at 72 h/initial parasitemia ± SD; values of survival
rates are expressed as (DHA-exposed parasitemia at 72 h/non-exposed parasitemia 72 h) x 100 ± SD. All experiments
were performed four times independently.
https://doi.org/10.1371/journal.pone.0191084.t002
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Fig 5. Statistical analysis of IC50 DHA in combination with MQ. PA and ARS1 were treated at rings stage (time 0)
with 0.6, 1.25, 2.5, 5, 10 nM DHA, alone or in combination with 5 nM and 10 nM of MQ, and analysed at 24 h (A), 48
h (B) and 72 h (C). Data were normalized to the parasitemia measured at time 0 and the IC50 was calculated using
ICEstimator software. Parasitemia was measured by microscopy of Giemsa-stained thin smears. Means +/- SD from 3
independent experiments is shown. Significant differences of parasitemia between strains are indicated by () at
p< 0.05, () at p< 0.01 and () at p< 0.001.
https://doi.org/10.1371/journal.pone.0191084.g005
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diversity from these genes exists among PA and ARS1 and indicating that we have not selected
a less represented strain that may have contaminated the parental strain.
The culmination of these results obtained form this study indicate that the ARS1 strain can
be useful to better understand the mechanisms of ART resistance and for the evaluation of
new antimalarial therapies in future studies.
Discussion
Through a series of treatment with low concentrations of DHA, we selected for the P. falcipa-
rum artemisinin resistance strain (ARS1) that arose from the parental strain PA. The ARS1
resistant phenotype was maintained under monthly sub-lethal concentrations of DHA.
The study of Brauner et al. helps to define the phenotype observed in ARS1 as a state of “tol-
erance”, which is the capability of parasites to survive transient exposure to drugs, also without
a consistent increase variation of IC50 [56].
Alarmingly, P. falciparum resistance to partner drugs along with ART in combination ther-
apies has been detected, leaving populations in South East Asia vulnerable to deadly malaria
infections [49, 28, 50]. For these reasons, a better understanding of the resistance mechanism
will help the selection of more effective and resistance tolerant antimalarial therapies.
In the drug discovery pipeline, identifying target genes or molecules responsible for a drug,
resistance phenotype is the first step in a 12–15 years process followed by high throughput
screening for a candidate antimalarial compounds [57]. Despite artemisinin resistant isolates
may more representative than ARS1, this could be an essential tool not only to elucidate the
underlying mechanisms of artemisinin resistance but also to evaluate the efficacy of new com-
pounds against these artemisinin resistant parasites.
To this end, we first evaluated the response of three artemisinin sensitive strains (PA, FCR3
and HB3A) to DHA, the active metabolite of all ART. Cultures were treated with low doses of
DHA for 8 weeks to select for parasites demonstrating a drug tolerant phenotype. While many
studies [25, 26] use high DHA concentrations (from 280 to 1200 nM) to generate resistant para-
sites, our method has the intended consequence of producing parasites that not enter a dormant
or quiescent state, a state not demonstrated in patients. Our method intentionally prevents the
accumulation of dormant parasites, using a maximum concentration of 5 nM DHA.
The artemisinin resistance phenotype of ARS1 is defined by the following features: i) adap-
tation to DHA is stable and can be maintained in drug-free medium for an extended period
(at least 1 month); ii) a 3-fold increase in DHA IC50 values relative to the parental strain after
72 h (2 nM in ARS1 and 0.68 nM in PA); iii) a reduced susceptibility of ARS1 to repetitive
pressure with low concentrations of DHA; iv) the ability to survive after a single pulse of 700
nM (PA: 0.51%, ARS1: 6.8%); v) resistance that appears specific to DHA, with no cross-resis-
tance to other antimalarial drugs.
It should be, anyway, noted that, although ARS1 presents a consistent 3-fold increase of the
DHA IC50 over its parental strain, the DHA IC50s of HB3A and ARS1 are similar, therefore,
the IC50 should not be considered as an absolute index of ART resistance. On the contrary,
ARS1 complies with the definition artemisinin resistant parasites, while no resistance was
measurable in parental strain [32, 47]; as previously described by Witkowski, two strains with
respectively1% vs1% of survival rate following 700 nM DHA treatment of survival rate, as
PA and ARS1, are generally defined as sensitive and resistant strain.
Moreover, there was no presence of cross-resistance to other commonly used antimalarials
and no increase in DHA sensitivity when combined with MQ (DHA-MQ). Despite we
shouldn’t consider the IC50 value as an ART resistance index, in this case could be an impor-
tant parameter to evaluate the tolerance of ARS1 to the MQ-DHA combination. It appears
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that ARS1 is selectively tolerant to DHA while maintaining its sensitivity to antimalarials pres-
ent in ACTs [58, 59].
Although studies investigating the cause of artemisinin resistance are plentiful, the exact
mechanism of resistance remains unclear. We postulated that a randomized molecular muta-
tion caused the acquired resilience to DHA observed in ARS1 progeny. Genetic sequencing of
the molecular markers msp1, msp2 and glurp eliminated the possibility ARS1 acquired muta-
tions in genes that are commonly used to discriminate parasite recrudescence from re-infec-
tion alleles in patients and was consistent with ARS1 arising from PA [53]. A mutation in the
recently discovered Pfk13 propeller domain was also not found. A mutation in this domain
would be consistent with other reports suggesting its association with artemisinin resistance in
field isolates. The lack of Pfk13 propeller mutations observed in ARS1 cannot be interpreted
due to the substantial lack of knowledge pertaining to the ART’ mechanism of action and to
the mutation’s heterogeneity associated with delayed parasite clearance in different geographic
populations [36]. However, it is of interest to further evaluate the cause of artemisinin resis-
tance in this case and evaluate ARS1 for a ubiquitous source of the resistance phenotype.
In conclusion, the data obtained in the present study confirm the ability of P. falciparum
cultures to become less responsive to DHA. We propose the ARS1 strain as a potential tool to
study artemisinin resistance mechanisms and to test new antimalarial compounds.
Supporting information
S1 Fig. Representative images of P. falciparum cultures from the RSA0-3h. PA and ARS1
were treated with 700 nM of DHA. The survival of both cultures was monitored at time 0, 24
h, 72 h and 7 days following the addition of DHA. Parasites were monitored by Diff-Quick
stained smears light microscopy using a 100x oil-immersion objective.
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